Crixivan is hard to get

April 1996

Crixivan is hard to get. Merck can not produce it fast enough, and they're limiting the number of patients started on it.

The big concern is that if patients have trouble getting it...and they stop and restart their therapy...resistance will build up faster.

Make sure patients are committed to being compliant before you add a protease inhibitor to their regimen. Patients even have to be prepared to suffer through the side effects.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote